{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "33595881",
  "DateCompleted": {
    "Year": "2021",
    "Month": "06",
    "Day": "30"
  },
  "DateRevised": {
    "Year": "2022",
    "Month": "12",
    "Day": "07"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2021",
        "Month": "03",
        "Day": "01"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "e13319",
      "10.1111/cmi.13319"
    ],
    "Journal": {
      "ISSN": "1462-5822",
      "JournalIssue": {
        "Volume": "23",
        "Issue": "7",
        "PubDate": {
          "Year": "2021",
          "Month": "Jul"
        }
      },
      "Title": "Cellular microbiology",
      "ISOAbbreviation": "Cell Microbiol"
    },
    "ArticleTitle": "Advanced microscopy technologies enable rapid response to SARS-CoV-2 pandemic.",
    "Pagination": {
      "StartPage": "e13319",
      "MedlinePgn": "e13319"
    },
    "Abstract": {
      "AbstractText": [
        "The ongoing SARS-CoV-2 pandemic with over 80 million infections and more than a million deaths worldwide represents the worst global health crisis of the 21th century. Beyond the health crisis, the disruptions caused by the COVID-19 pandemic have serious global socio-economic consequences. It has also placed a significant pressure on the scientific community to understand the virus and its pathophysiology and rapidly provide anti-viral treatments and procedures in order to help the society and stop the virus spread. Here, we outline how advanced microscopy technologies such as high-throughput microscopy and electron microscopy played a major role in rapid response against SARS-CoV-2. General applicability of developed microscopy technologies makes them uniquely positioned to act as the first line of defence against any emerging infection in the future."
      ],
      "CopyrightInformation": "\u00a9 2021 The Authors. Cellular Microbiology published by John Wiley & Sons Ltd."
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Infectious Diseases, Molecular Virology, University Hospital Heidelberg, Heidelberg, Germany."
          }
        ],
        "LastName": "Cortese",
        "ForeName": "Mirko",
        "Initials": "M"
      },
      {
        "Identifier": [
          "0000-0002-9472-2738"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Infectious Diseases, Virology, University Hospital Heidelberg, Heidelberg, Germany."
          },
          {
            "Identifier": [],
            "Affiliation": "German Center for Infection Research, Heidelberg, Germany."
          }
        ],
        "LastName": "Laketa",
        "ForeName": "Vibor",
        "Initials": "V"
      }
    ],
    "GrantList": [
      {
        "GrantID": "TTU 04.705",
        "Agency": "Deutsches Zentrum f\u00fcr Infektionsforschung",
        "Country": ""
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Research Support, Non-U.S. Gov't",
      "Review"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "India",
    "MedlineTA": "Cell Microbiol",
    "NlmUniqueID": "100883691",
    "ISSNLinking": "1462-5814"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antibodies, Viral"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antiviral Agents"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "COVID-19 Vaccines"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "blood"
      ],
      "DescriptorName": "Antibodies, Viral"
    },
    {
      "QualifierName": [
        "pharmacology"
      ],
      "DescriptorName": "Antiviral Agents"
    },
    {
      "QualifierName": [
        "diagnosis",
        "pathology",
        "virology"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [],
      "DescriptorName": "COVID-19 Serological Testing"
    },
    {
      "QualifierName": [],
      "DescriptorName": "COVID-19 Vaccines"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Cryoelectron Microscopy"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Drug Development"
    },
    {
      "QualifierName": [],
      "DescriptorName": "High-Throughput Screening Assays"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "methods"
      ],
      "DescriptorName": "Microscopy"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Microscopy, Electron"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Pandemics"
    },
    {
      "QualifierName": [
        "drug effects",
        "immunology",
        "physiology",
        "ultrastructure"
      ],
      "DescriptorName": "SARS-CoV-2"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Virus Replication"
    },
    {
      "QualifierName": [],
      "DescriptorName": "COVID-19 Drug Treatment"
    }
  ]
}